Photodynamic therapy of intraductal papillary mucinous neoplasm

Intraductal papillary mucinous neoplasm (IPMN) of the main pancreatic duct is usually treated by surgical excision of the affected pancreas. Nonoperative ablative therapies have not been described. We treated IPMN of the pancreatic duct with photodynamic therapy (PDT) in a patient who was a poor operative candidate. Porfimer sodium was administered intravenously, and laser light was delivered by a diffusing catheter placed in the pancreatic duct during endoscopic retrograde cholangiopancreatography (ERCP). Imaging and biopsy findings of IPMN resolved after PDT, and symptoms also resolved. Metastatic cancer was diagnosed 2 years after PDT had been initiated. Pancreatic PDT was well tolerated in this case, and may be a therapeutic option for selected patients with IPMN of the main pancreatic duct.

• References

• 1 Cellier C, Cuillerier E, Palazzo L et al. Intraductal papillary and mucinous tumors of the pancreas: accuracy of preoperative computed tomography, endoscopic retrograde pancreatography and endoscopic ultrasonography, and long-term outcome in a large surgical series. Gastrointest Endosc 1998; 47: 42-49
• 2 Hara T, Yamaguchi T, Ishihara T et al. Diagnosis and patient management of intraductal papillary-mucinous tumor of the pancreas by using peroral pancreatoscopy and intraductal ultrasonography. Gastroenterology 2002; 122: 34-43
• 3 Hruban R, Takaori K, Klimstra D et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004; 28: 977-987
• 4 Levy P, Jouannaud V, O’Toole D et al. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol 2008; 4: 460-468
• 5 Tanaka M, Chari S, Adsay V et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6: 17-32
• 6 Wang J, Liu L. Use of photodynamic therapy in malignant lesions of stomach, bile duct, pancreas, colon and rectum. Hepato-Gastroenterology 2007; 54: 718-724
• 7 Overholt B, Wang K, Burdick J et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007; 66: 460-468
• 8 Prasad G, Wu T, Wigle D et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology 2009; 137: 815-823
• 9 Ortner M, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363
• 10 Prasad G, Wang K, Baron T et al. Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma. Clin Gastroenterol Hepatol 2007; 5: 743-748
• 11 Fan B, Andren-Sandberg A. Photodynamic therapy for pancreatic cancer. Pancreas 2007; 34: 385-389
• 12 Yusuf T, Matthes K, Brugge W. EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video). Gastrointest Endosc 2008; 67: 957-961
• 13 Bown S, Rogowska A, Whitelaw D et al. Photodynamic therapy for cancer of the pancreas. Gut 2002; 50: 549-557
• 14 Schroder T, Chen I, Sperling M et al. Hematoporphyrin derivative uptake and photodynamic therapy in pancreatic carcinoma. J Surg Oncol 1988; 38: 4-9
• 15 Shin S, Han D, Park K et al. Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg 2010; 34: 776-783
• 16 Uehara H, Ishikawa O, Ikezawa K et al. A natural course of main duct intraductal papillary mucinous neoplasm of the pancreas with lower likelihood of malignancy. Pancreas 2010; 39: 653-657
• 17 Turrini O, Waters J, Schnelldorfer T et al. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. HPB (Oxford) 2010; 12: 447-455